QR-koda

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy

Abstract Acute myeloid leukemia (AML), especially therapy-related (t-AML) or secondary AML (s-AML), presents complex therapeutic challenges. CPX-351, a liposomal formulation of cytarabine and daunorubicin, has demonstrated superior outcomes compared to standard 7 + 3 chemotherapy. However, optimal p...

Olles dieđut

Furkejuvvon:
Váldodahkkit: Salvatore Perrone, Andrea Corbingi, Calogero Vetro, Fanny Erika Palumbo, Paola Minetto, Carola Riva, Laura Cicconi, Chiara Vernarecci, Roberto Massimo Lemoli, Alessandro Pulsoni, Fabio Guolo
Materiálatiipa: Artigo
Giella:Inglês
Almmustuhtton: Springer 2026-02-01
Ráidu:Annals of Hematology
Fáttát:
Acute myeloid leukemia
CPX-351
Consolidation
ARA-C
Real-world evidence
Liŋkkat:https://doi.org/10.1007/s00277-026-06784-w
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid